Bioventus Inc.

Total Valuation

Bioventus Inc. carries a market capitalization of 953.22M, placing it among publicly traded companies globally. Its enterprise value stands at 912.02M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Bioventus Inc. currently has 68.21M shares outstanding.

Valuation Ratios

Bioventus Inc. trades at a trailing price-to-earnings ratio of 11.66. The price-to-sales ratio is 1.09, and the price-to-book ratio stands at 2.82.

Enterprise Valuation

On an enterprise value basis, Bioventus Inc. trades at an EV/EBITDA multiple of 8.62 and an EV/FCF ratio of 6.96. The EV/Sales ratio of 1.57 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 15.06 provides insight into valuation relative to core operating earnings.

Financial Position

Bioventus Inc. maintains a current ratio of 1.69, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 89.56, indicating elevated leverage, while an interest coverage ratio of 5.32 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Bioventus Inc. has paid -22.84M in income taxes, reflecting an effective tax rate of 26.86.

Stock Price Statistics

Bioventus Inc.'s stock has gained approximately 95.14563% over the past 52 weeks. The 50-day moving average sits at 12.88, while the 200-day moving average is 9.70.

Income Statement

Over the trailing twelve months, Bioventus Inc. generated 581.85M in revenue and converted that into 54.46M in net income, yielding earnings per share of 0.88. EBITDA reached 105.80M, while operating income came in at 60.55M.

Balance Sheet

Bioventus Inc. holds 29.46M in cash and equivalents against 248.45M in total debt, resulting in a net debt position of 219.00M. Total book value stands at 228.31M, with working capital of 105.08M providing operational flexibility.

Cash Flow

Bioventus Inc. produced 96.87M in operating cash flow over the past twelve months. After subtracting -2.59M in capital expenditures, free cash flow totaled 94.29M - equivalent to 1.40 per share.

Margins

Bioventus Inc. operates with a gross margin of 68.65, reflecting its pricing power and cost economics. The operating margin of 10.41 and net profit margin of 9.36 provide insight into operational efficiency.

Dividends & Yields

Scores

Bioventus Inc. posts an Altman Z-Score of 2.53, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.